Causes of retention of urine
| Type | Features |
|---|---|
| Acute | Sudden, painful inability to void; bladder palpable, tense, dull |
| Chronic | Gradual, painless accumulation; patient may be unaware; may present with overflow incontinence or frequency |
| Acute-on-chronic | Chronic retention with sudden painful exacerbation, often triggered by infection |
| Cause | Cases |
|---|---|
| Benign prostatic hyperplasia | 193 |
| Malignant disease of prostate | 39 |
| Urethral stricture | 23 |
| Phimosis | 14 |
| Vesical tumour (clot retention) | 9 |
| Inflammation (cystitis/prostatitis) | 4 |
| Spinal injury | 4 |
| Neurological disease | 4 |
| Impacted urethral calculus | 3 |
| Rupture of urethra | 2 |
| Papilloma of urethra | 1 |
| Miscellaneous (drugs, constipation) | 4 |
Homeopathic therapeutic of urinary tract infections
homeopathic remedies urinary tract infection Cantharis Apis Staphysagria materia medica
https://www.peacehealth.org/medical-topics/id/hn-2262002
homeopathy "urinary tract infection" treatment
Important note: The medical textbook library does not contain homeopathic texts. The information below is drawn from established homeopathic materia medica, clinical prescribing references (including PeaceHealth Health Library), and published case literature. Homeopathic prescribing is highly individualised - the remedy is matched to the total symptom picture of the patient, not just the diagnosis. Patients with fever, kidney pain, or severe symptoms should seek conventional medical evaluation, as ascending UTIs (pyelonephritis) require antibiotic therapy.
| Remedy | Key Indication |
|---|---|
| Aconitum napellus | Sudden onset after exposure to cold; anxiety before and during urination; hot, scanty urine; retention from chill or shock |
| Clematis | Constriction in urethra; interrupted flow; dribbling after urination; tingling lasting long after |
| Equisetum (Horsetail) | Dull, distressing pain with fullness even after voiding; urging worse when bladder is empty |
| Lycopodium | Right-sided affinity; red sediment in urine; craving sweets; 4-8 PM aggravation |
| Borax | UTI with anxiety; downward motion aggravates; useful in children |
| Pulsatilla | Bland, changeable symptoms; worse lying down; patient is yielding, weepy, craves open air; no thirst |
| Sepia | Chronic/recurrent UTIs in women; bearing-down sensation; indifferent; worse before menses |
| Situation | Remedy to Consider |
|---|---|
| Post-coital cystitis | Staphysagria |
| After catheterisation | Staphysagria |
| After cold/chill | Aconitum |
| With renal colic/stones | Berberis vulgaris, Sarsaparilla |
| Haematuria prominent | Cantharis, Terebenthina |
| Ascending UTI / kidney involvement | Terebenthina (urine smells of violets - keynote), Berberis |
| Recurrent UTIs (constitutional) | Sepia, Medorrhinum, Colibacillinum |
| UTI in irritable/stressed individual | Nux vomica, Staphysagria |
| Symptom Keynote | Remedy |
|---|---|
| Burning before + during + after urination, drops only | Cantharis |
| Stinging at last drops, no thirst, swelling | Apis mellifica |
| Post-coital UTI, drop rolling sensation | Staphysagria |
| Pain worst at END of urination, better standing | Sarsaparilla |
| Radiating/shooting pain, worse walking | Berberis vulgaris |
| Sudden onset after cold, anxiety | Aconitum |
| Irritable patient, chilly, constant urge | Nux vomica |
| Highly coloured urine, bladder sensitivity, cramping | Belladonna |
| Urine smells of violets, haematuria + kidney pain | Terebenthina |
Staging of breast cancer.
| Type | Based On | Used When |
|---|---|---|
| Anatomic Staging | Tumour size (T), nodal status (N), metastasis (M) | Biomarker data unavailable; resource-limited settings |
| Prognostic Staging | TNM + Grade + ER/PR/HER2 + Oncotype DX score | Standard in countries where biomarkers are routinely tested |
| Category | Definition |
|---|---|
| Tx | Primary tumour cannot be assessed |
| T0 | No evidence of primary tumour |
| Tis | Carcinoma in situ: DCIS, or Paget disease of nipple with no underlying tumour. Note: LCIS is now classified as a benign high-risk lesion, NOT as Tis |
| T1 | Tumour ≤ 20 mm in greatest dimension |
| - T1mi | Microinvasion: invasive focus ≤ 1 mm |
| - T1a | > 1 mm but ≤ 5 mm |
| - T1b | > 5 mm but ≤ 10 mm |
| - T1c | > 10 mm but ≤ 20 mm |
| T2 | Tumour > 20 mm but ≤ 50 mm |
| T3 | Tumour > 50 mm |
| T4 | Tumour of any size with direct extension to chest wall (not including pectoralis muscle alone) and/or skin changes |
| - T4a | Extension to chest wall |
| - T4b | Ulceration, skin oedema (including peau d'orange), or satellite skin nodules (satellite nodules must be separate from the primary tumour) |
| - T4c | Both T4a and T4b |
| - T4d | Inflammatory carcinoma - skin changes involving ≥ 1/3 of the breast skin (erythema, peau d'orange). Remains classified as T4d even if complete remission follows neoadjuvant chemotherapy |
| Category | Definition |
|---|---|
| cNx | Regional lymph nodes cannot be assessed |
| cN0 | No regional lymph node metastases (by imaging/examination) |
| cN1 | Movable ipsilateral level I/II axillary lymph node(s) with metastases |
| cN2 | Fixed/matted ipsilateral axillary nodes (cN2a); or clinically detected ipsilateral internal mammary nodes without axillary involvement (cN2b) |
| cN3 | Metastases in infraclavicular nodes (cN3a); or internal mammary + axillary nodes (cN3b); or ipsilateral supraclavicular nodes (cN3c) |
| Category | Definition |
|---|---|
| pN0 | No regional lymph node metastases histologically |
| pN0(i+) | Isolated tumour cells: clusters ≤ 0.2 mm |
| pN1mi | Micrometastases: > 0.2 mm but none > 2.0 mm (or > 200 cells) |
| pN1 | Metastases in 1-3 axillary nodes, and/or internal mammary nodes by SLN biopsy (not clinically detected) |
| pN2 | Metastases in 4-9 axillary nodes; or clinically detected internal mammary nodes without axillary involvement |
| pN3 | Metastases in ≥ 10 axillary nodes; or infraclavicular (level III) nodes; or clinically detected internal mammary nodes + ≥1 positive axillary node; or >3 axillary nodes + internal mammary micrometastases; or ipsilateral supraclavicular nodes |
| Category | Definition |
|---|---|
| M0 | No clinical or radiographic evidence of distant metastasis |
| cM0(i+) | Circulating tumour cells or disseminated tumour cells in bone marrow (≤ 0.2 mm) detected molecularly/microscopically; no clinical symptoms |
| M1 | Distant metastasis - common sites: bone, lung, liver, brain |
| Stage | T | N | M |
|---|---|---|---|
| Stage 0 | Tis | N0 | M0 |
| Stage IA | T1 (incl. T1mi) | N0 | M0 |
| Stage IB | T0 or T1 | N1mi | M0 |
| Stage IIA | T0 or T1 | N1 | M0 |
| T2 | N0 | M0 | |
| Stage IIB | T2 | N1 | M0 |
| T3 | N0 | M0 | |
| Stage IIIA | T0, T1, T2 | N2 | M0 |
| T3 | N1 or N2 | M0 | |
| Stage IIIB | T4 | N0, N1, or N2 | M0 |
| Stage IIIC | Any T | N3 | M0 |
| Stage IV | Any T | Any N | M1 |
| Factor | Detail |
|---|---|
| Histologic Grade | Nottingham grading system (Grade 1/2/3) - now standardised and required |
| ER status | Estrogen receptor (positive/negative by IHC) |
| PR status | Progesterone receptor (positive/negative) |
| HER2 status | HER2/neu amplification (positive/negative/equivocal) |
| Oncotype DX Recurrence Score | Multigene panel - the only multigene assay currently incorporated; applies to ER+/HER2- early-stage disease; score ≤ 25 in postmenopausal women with 1-3 positive nodes may allow omission of chemotherapy (RxPONDER trial) |
Effect: A tumour that is anatomically Stage II but is ER+/PR+/HER2-, low grade, with a low Oncotype DX score may be downstaged to a more favourable prognostic stage. Conversely, a triple-negative or HER2+ tumour may be upstaged prognostically.
| Notation | Meaning |
|---|---|
| cTNM | Clinical staging (pre-treatment; physical exam + imaging + biopsy) |
| pTNM | Pathologic staging (post-surgery; preferred when available) |
| ypTNM | Post-neoadjuvant therapy pathologic staging |
| rTNM | Recurrent tumour staging |
| pT(m)NM | Multiple synchronous primary tumours (m = multiple) |
| pCR | Pathologic complete response - absence of tumour in breast AND axillary nodes after neoadjuvant therapy |
| Stage | Investigations |
|---|---|
| Early (T1-T2, N0-N1) | Bilateral breast imaging (mammogram ± MRI); metastatic workup only if symptoms or raised ALP |
| Locally advanced (T3-T4 or N2-N3) | CE-CT chest/abdomen/pelvis + isotope bone scan; PET-CT with 18F-FDG may be used |
| All stages | ER, PR, HER2, Ki-67, grade from tumour biopsy |